LPTX_OUT_1 [2025-03-26 08:26:08 -0400] 1999 Bytes | 540 tokens | Cum: 540 tkns (6.75% of 8k)
==========================================================================

Listen up, partner—it's 8:26:06 AM on Wed Mar 26, 2025 -0400, and I’m revved up about Leap Therapeutics (LPTX), climbing from 0.388 to 0.4774. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

Here's the first list of news for Leap Therapeutics:

C1 - Today 07:05AM - Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
C2 - 07:00AM - Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study
C3 - Jan-28-25 07:00AM - Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study
C4 - Jan-06-25 07:00AM - Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference
C5 - Nov-26-24 07:00AM - Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference
C6 - Nov-13-24 07:00AM - Leap Therapeutics Reports Third Quarter 2024 Financial Results
C7 - Sep-30-24 07:00AM - Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients
C8 - Aug-12-24 07:00AM - Leap Therapeutics Reports Second Quarter 2024 Financial Results

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Leap Therapeutics (LPTX)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

LPTX_OUT_3 [2025-03-26 08:26:09 -0400] 1039 Bytes | 276 tokens | Cum: 818 tkns (10.22% of 8k)
==========================================================================

Showing C1 (chunk 1 of 11): C1:
**Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results**
Date: Today 07:05AM
Source: (PR Newswire)
URL: https://www.prnewswire.com/news-releases/leap-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-302411353.html

Leap to host a conference call to present updated CRC clinical data today,March 26, 2025, at8:00 a.m. ET

CAMBRIDGE, Mass.,March 26, 2025/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year endedDecember 31, 2024.

"In 2024, we continued to advance sirexatamab, our anti-DKK1antibody, through Phase 2 randomized controlled clinical trials as part of our mission to bring personalized medicines to patients fighting against cancer. In particular, the updated data from Part B o

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

LPTX_OUT_5 [2025-03-26 08:26:11 -0400] 863 Bytes | 240 tokens | Cum: 1060 tkns (13.25% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-26T11:05:00Z - Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - Leap Therapeutics (N...
A2 - 2025-03-26T11:08:44Z - Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results...
A3 - 2025-03-26T11:08:44Z - Leap Therapeutics (LPTX) Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study...
A4 - 2025-03-11T17:25:54Z - Leap Therapeutics stock hits 52-week low at $0.4 amid sharp decline By Investing.com...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

LPTX_OUT_7 [2025-03-26 08:26:12 -0400] 1039 Bytes | 297 tokens | Cum: 1359 tkns (16.99% of 8k)
==========================================================================

Showing A1 (chunk 1 of 17): A1:
**Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - Leap Therapeutics (NASDAQ:LPTX)**Date: 2025-03-26Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/pressreleases/25/03/n44490487/leap-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-resultsLeap to host a conference call to present updated CRC clinical data today, March 26, 2025, at 8:00 a.m. ET

CAMBRIDGE, Mass., March 26, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. LPTX, a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2024.

Leap Highlights:

Reported positive updated data from Part B of the Phase 2 DeFianCe study of sirexatamab (DKN-01) in second-line patients with advanced microsatellite stable (MSS) colorect

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

LPTX_OUT_9 [2025-03-26 08:26:20 -0400] 1039 Bytes | 247 tokens | Cum: 1608 tkns (20.10% of 8k)
==========================================================================

Showing A1 (chunk 2 of 17): al cancer (CRC) confirming:Statistically significant 32% higher overall response rate (ORR), 3.5 month longer progression-free survival (PFS), and longer overall survival (OS) in patients with high DKK1 levelsStatistically significant 22% higher ORR and 2.6 month longer PFS in patients who had not had prior anti-VEGF therapyFL-501 abstract accepted for poster presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting.

"In 2024, we continued to advance sirexatamab, our anti-DKK1 antibody, through Phase 2 randomized controlled clinical trials as part of our mission to bring personalized medicines to patients fighting against cancer. In particular, the updated data from Part B of the DeFianCe study that we announced today demonstrated significantly higher ORR and longer PFS for sirexatamab in patients who have high levels of DKK1 or who have not had prior anti-

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

LPTX_OUT_11 [2025-03-26 08:26:21 -0400] 1039 Bytes | 248 tokens | Cum: 2008 tkns (25.10% of 8k)
==========================================================================

Showing A1 (chunk 3 of 17): VEGF therapy, two exploratory populations with strong scientific rationale that each represent 25-50% of the second-line CRC market," said Douglas E. Onsi, President and Chief Executive Officer of Leap. "We believe that there is a compelling opportunity to move forward with a registrational study for sirexatamab in patients with CRC and to advance FL-501 towards clinical trials."

DKN-01 Development Update

Reported updated clinical data from Part B of the DeFianCe Study of sirexatamab plus bevacizumab and chemotherapy in CRC patients. Today, the Company announced updated preliminary data from Part B of the DeFianCe study (NCT05480306), a Phase 2, open-label, global study of sirexatamab in combination with bevacizumab and chemotherapy (Experimental Arm) compared to bevacizumab and chemotherapy (Control Arm) in patients with MSS CRC who have received one prior systemic therapy for advance

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

LPTX_OUT_13 [2025-03-26 08:26:23 -0400] 1000 Bytes | 314 tokens | Cum: 2324 tkns (29.05% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-03-20T13:35:03Z - Here's Why Leap Therapeutics (LPTX) is Poised for a Turnaround After Losing -28.92% in 4 Weeks
B2 - 2023-11-24T17:21:14Z - Why FLJ Group Shares Are Trading Higher By Around 96%? Here Are Other Stocks Moving In Friday's Mid-Day Session
B3 - 2023-11-14T17:00:35Z - Raymond James Maintains Outperform Rating for Leap Therapeutics: Here's What You Need To Know
B4 - 2023-06-06T17:04:02Z - Why THOR Industries Shares Are Trading Higher By 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
B5 - 2023-05-18T19:25:32Z - 3 Hot Penny Stocks To Watch Under $1, Time To Buy?
B6 - 2023-05-18T17:19:03Z - Why Monro Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

LPTX_OUT_15 [2025-03-26 08:26:28 -0400] 671 Bytes | 180 tokens | Cum: 2506 tkns (31.32% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Here's Why Leap Therapeutics (LPTX) is Poised for a Turnaround After Losing -28.92% in 4 Weeks**Date: Unknown DateSource: Unknown SourceURL: https://www.zacks.com/stock/news/2243368/heres-why-leap-therapeutics-lptx-is-poised-for-a-turnaround-after-losing--2892-in-4-weeksLeap Therapeutics (LPTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

LPTX_OUT_17 [2025-03-26 08:26:29 -0400] 1093 Bytes | 273 tokens | Cum: 2849 tkns (35.61% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-26 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes appearing elsewhere ...

S2 - 2025-03-26 8-K Item 2.02. Results of Oper and Fin Cond

On March 26, 2025, Leap Therapeutics, Inc. (the Company) announced its financial results for the fourth quarter and year ended December 31, 2024. The full text of the press release issued by the Company in connection with...

S3 - 2024-11-13 8-K Item 2.02. Results of Oper and Fin Cond

On November 13, 2024, Leap Therapeutics, Inc. (the Company) announced its financial results for the quarter ended September 30, 2024. The full text of the press release issued by the Company in connection with the announc...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

LPTX_OUT_19 [2025-03-26 08:26:31 -0400] 1038 Bytes | 205 tokens | Cum: 3056 tkns (38.20% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes appearing elsewhere in this Annual Report on Form 10 -K. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors. We discuss factors that we believe could cause or contribute to these differences below and elsewhere in this report, including those set forth under Item 1A. Risk Factors and under Cautionary Note Regarding Forward-Looking Statements in this Annual Report.

Overview

We are a biopharmaceut

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

LPTX_OUT_21 [2025-03-26 08:26:47 -0400] 4220 Bytes | 1183 tokens | Cum: 4241 tkns (53.01% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+----------------------+-------------------------+------------------------+----------------------+
| Volume: 272,265 | SMA50: -56.66% | Market Cap: 14.87M | Option/Short: Yes / Yes | Sales past 5Y: -25.00% | Sales Surprise: - |
+---------------------+-----------------------+----------------------+-------------------------+------------------------+----------------------+
| Avg Volume: 756.73K | SMA200: -82.53% | Shs Outstand: 38.26M | Short Float: 6.62% | Employees: 54 | EPS Surprise: 10.93% |
+---------------------+-----------------------+----------------------+-------------------------+------------------------+----------------------+
| Rel Volume: 0.35 | Perf Week: -4.22% | Shs Float: 28.57M | Short Ratio: 2.50 | Debt/Eq: 0.01 | P/E: - |
+---------------------+-----------------------+----------------------+-------------------------+------------------------+----------------------+
| RSI (14): 23.45 | Perf Month: -19.33% | Inst Own: 30.21% | Short Interest: 1.89M | Sales Y/Y TTM: - | Earnings: Nov 13 BMO |
+---------------------+-----------------------+----------------------+-------------------------+------------------------+----------------------+
| ATR (14): 0.05 | Perf Quarter: -86.04% | Insider Own: 25.44% | Beta: 0.09 | ROE: -106.79% | |
+---------------------+-----------------------+----------------------+-------------------------+------------------------+----------------------+
| SMA20: -8.06% | Index: - | Insider Trans: 0.00% | Sales Q/Q: - | ROI: -131.94% | |
+---------------------+-----------------------+----------------------+-------------------------+------------------------+----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -64589000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.388
Average Volume: 280618.86
30-Day High: 0.483
30-Day Low: 0.388

[Detailed Financials: Q3 2024]
- Total Assets: $65,047,000.0
- Total Liabilities: $16,093,000.0
- Total Equity: $48,954,000.0
- Current Assets: $63,812,000.0
- Current Liabilities: $16,093,000.0

[Income Statement: Q3 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.44

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-10,000

[Detailed Financials: Q2 2024]
- Total Assets: $81,426,000.0
- Total Liabilities: $15,638,000.0
- Total Equity: $65,788,000.0
- Current Assets: $79,587,000.0
- Current Liabilities: $15,599,000.0

[Income Statement: Q2 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.52

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $-112,000
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

LPTX_OUT_23 [2025-03-26 08:26:55 -0400] 676 Bytes | 167 tokens | Cum: 4635 tkns (57.94% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

LPTX_IN_25 [2025-03-26 08:26:56 -0400] 126 Bytes | 29 tokens | Cum: 4764 tkns (59.55% of 8k)
==========================================================================

====================================
[2025-03-26 05:26:56] # Analysis Completed
Elapsed Time: 49.88 seconds